Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

Secretary of the Senate Received: Feb 13, 2006

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

X Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

1. Registrant Name: GLAXOSMITHKLINE 1500 K STREET, NW SUITE 650, WASHINGTON, DC 20005 3. Principal place of business (if different from line 2): Country City: State/Zip(or Country): 4. Contact Name: SARAH J. WALSH Telephone: 202-715-1015 E-mail (optional): sally.j.walsh@gsk.com Senate ID #: 16293-12 House ID #: 31461000 7. Client Name: X Self TYPE OF REPORT \_\_ Midyear (January 1 - June 30): 🔲 OR Year End (July 1 - December 31): 🔀 9. Check if this filing amends a previously filed version of this report: 10. Check if this is a Termination Report: 

=> Termination Date: 11. No Lobbying Activity: INCOME OR EXPENSES Complete Either Line 12 OR Line 13 12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000: -\$10,000 or more: => Income (nearest \$20,000);\_ Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 13. Organizations EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000: -\$10,000 or more: |X| => Expenses (nearest \$20,000): 2,860,000.00 14. Reporting Method. Check box to indicate expense accounting method. See instructions for description of options.

Page 1

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as

- 15. General issue area code: CPT (one per page)
- 16. Specific lobbying issues:
- HR 2795 Patent Reform Act of 2005-infringement and continuation provisions.
- 17. House(s) of Congress and Federal agencies contacted:
- U. S. House of Representatives U. S. Senate
- 18. Name of each individual who acted as a lobbyist in this issue area:

Name: ELLING, DANIEL Covered Official Position (if applicable):

Name: KINNEY, JANIE

Covered Official Position (if applicable):

Name: MCLAIN, PATRICK

Covered Official Position (if applicable):

Name: SCHUYLER, WILLIAM

Covered Official Position (if applicable): Name: THEVENET, PHILIP

Covered Official Position (if applicable):

Name: WALSH, SARAH

Covered Official Position (if applicable):

Name: WILLIAMS, KIMBERLY

Covered Official Position (if applicable):

Name: YORK, ELIZABETH

Covered Official Position (if applicable):

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: HCR (one per page)
- 16. Specific lobbying issues:

H.R. 3010 Labor, HHS Appropriations Act of 2006-provisions: treatment of HIV H.R. 578 Prescription Drug Affordability Act H.R. 328 Pharmaceutical Market Access Act of 2005 S. 319 Pharmaceutical Market Access & Drug Safety Act of 2005 H.R. 700 Pharmaceutical Market Access & Drug Safety Act of 2005 H.R. 700 Pharmaceutical Market Access & Drug Safety Act of 2005 H.R. 563 Prescription Drug Affordability Act of 2005 H.R. 516 Class Action Fairness Act 2005 S. 5 Class Action Fairness Act of 2005 H.R. 2744 Agriculture Appropriations for 2006-provisions re: drug importation H.R. 2863 Defense Appropriations Act of 2006

17. House(s) of Congress and Federal agencies contacted: U.S. House of Representatives U.S. Senate Health & Human Services

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ELLING, DANIEL
Covered Official Position (if applicable):
Name: KINNEY, JANIE
Covered Official Position (if applicable):
Name: MCLAIN, PATRICK
Covered Official Position (if applicable):
Name: SCHUYLER, WILLIAM
Covered Official Position (if applicable):
Name: THEVENET, PHILIP
Covered Official Position (if applicable):
Name: WALSH, SARAH
Covered Official Position (if applicable):
Name: WILLIAMS, KIMBERLY
Covered Official Position (if applicable):
Name: YORK, ELIZABETH
Covered Official Position (if applicable):

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as

- 15. General issue area code: LBR (one per page)
- 16. Specific lobbying issues:
- S. 1783 Pension Security & Transparency Act of 2005 H. R. 2830 Pension Protection Act of 2005
- 17. House(s) of Congress and Federal agencies contacted:
- U. S. House of Representatives U. S. Senate
- 18. Name of each individual who acted as a lobbyist in this issue area:

Name: ELLING, DANIEL Covered Official Position (if applicable):

Name: KINNEY, JANIE

Covered Official Position (if applicable):

Name: MCLAIN, PATRICK

Covered Official Position (if applicable):

Name: SCHUYLER, WILLIAM

Covered Official Position (if applicable): Name: THEVENET, PHILIP

Covered Official Position (if applicable):

Name: WALSH, SARAH

Covered Official Position (if applicable):

Name: WILLIAMS, KIMBERLY

Covered Official Position (if applicable):

Name: YORK, ELIZABETH

Covered Official Position (if applicable):

Registrant Name: GLAXOSMITHKLINE Client Name: Self

### LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: MED (one per page)
- 16. Specific lobbying issues:

H.R. 881 Mercury-free Vaccines Act of 2005 S. 1051 HIV & AIDS Research CARE ACT of 2005 S. 975 Project BioShield II
Act of 2005-IP Provisions S. 375 Flu Protection Act of 2005 S. 470 Fair Access to Clinical Trials Act of 2005 H.R. 3196 Fair
Access to Clinical Trials Act of 2005 H.R. 4239 Animal Enterprise Act S. 1926 Animal Enterprise Act H.R. 650 Vaccines Act of 2005 S. 1873 Bio-Defense & Pandemic Vaccine & Drug Development Act of 2005

17. House(s) of Congress and Federal agencies contacted:
U.S. House of Representatives
U.S. Senate
Federal Trade Commission
Food & Drug Administration
National Institutes of Health
U.S. State Department

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ELLING, DANIEL
Covered Official Position (if applicable):
Name: KINNEY, JANIE
Covered Official Position (if applicable):
Name: MCLAIN, PATRICK
Covered Official Position (if applicable):
Name: SCHUYLER, WILLIAM
Covered Official Position (if applicable):
Name: THEVENET, PHILIP
Covered Official Position (if applicable):
Name: WALSH, SARAH
Covered Official Position (if applicable):
Name: WILLIAMS, KIMBERLY
Covered Official Position (if applicable):
Name: YORK, ELIZABETH
Covered Official Position (if applicable):

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as

- 15. General issue area code: MMM (one per page)
- 16. Specific lobbying issues:
- Medicare Prescription Drug Savings & Choice Act of 2005 S. 345 Medicare Prescription Drug Savings & Choice Act of 2005 H.R. 729 Medicare Drug Cost Credibility Act of 2005 H.R. 1626 Medicare Prescription Drug Improvement Act of 2005 H.R. 712 Medicare Prescription Drug Sensibility Act
- 17. House(s) of Congress and Federal agencies contacted:
- U.S. House of Representatives U.S. Senate
- 18. Name of each individual who acted as a lobbyist in this issue area:

Name: ELLING, DANIEL

Covered Official Position (if applicable):

Name: KINNEY, JANIE

Covered Official Position (if applicable):

Name: MCLAIN, PATRICK

Covered Official Position (if applicable):

Name: SCHUYLER, WILLIAM

Covered Official Position (if applicable): Name: THEVENET, PHILIP

Covered Official Position (if applicable):

Name: WALSH, SARAH

Covered Official Position (if applicable):

Name: WILLIAMS, KIMBERLY

Covered Official Position (if applicable):

Name: YORK, ELIZABETH

Covered Official Position (if applicable):

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as

- 15. General issue area code: TAX (one per page)
- 16. Specific lobbying issues:
- H.R. 575 Say No To Drug Ads Act
- 17. House(s) of Congress and Federal agencies contacted:
- U.S. House of Representatives U.S. Senate
- 18. Name of each individual who acted as a lobbyist in this issue area:

Name: ELLING, DANIEL Covered Official Position (if applicable):

Name: KINNEY, JANIE

Covered Official Position (if applicable):

Name: MCLAIN, PATRICK

Covered Official Position (if applicable):

Name: SCHUYLER, WILLIAM

Covered Official Position (if applicable): Name: THEVENET, PHILIP

Covered Official Position (if applicable):

Name: WALSH, SARAH

Covered Official Position (if applicable):

Name: WILLIAMS, KIMBERLY

Covered Official Position (if applicable):

Name: YORK, ELIZABETH

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

Signature: ON FILE Date: Feb 13, 2006

Printed Name and Title: Sarah J. Walsh, Vice President, Federal Government -